The DOI matches its Crossref record.
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
Open accessAbstract
PURPOSE: This phase I study, which to our knowledge is the first-in-human study of this kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of anetumab ravtansine, an antibody–drug conjugate of anti-mesothelin antibody linked to maytansinoid DM4, in patients with advanced, metastatic, or recurrent solid tumors known to express the tumor-differentiation antigen mesothelin. PATIENTS AND METHODS: This phase I, open-label, multicenter, dose-escalation and dose-expansion study of anetumab ravtansine enrolled 148 adult patients with multiple solid tumor types. Ten dose-escalation cohorts of patients with advanced or metastatic solid tumors (0.15-7.5 mg/kg) received anetumab ravtansine once every 3 weeks, and 6 expansion cohorts of patients with advanced, recurrent ovarian cancer or malignant mesothelioma received anetumab ravtansine at the maximum tolerated dose once every 3 weeks, 1.8 mg/kg once per week, and 2.2 mg/kg once per week. RESULTS: Forty-five patients were enrolled across the 10 dose-escalation cohorts. The maximum tolerated dose of anetumab ravtansine was 6.5 mg/kg once every 3 weeks or 2.2 mg/kg once per week. Thirty-two patients were enrolled in the 6.5 mg/kg once-every-3-weeks, 35 in the 1.8 mg/kg once-per-week, and 36 in the 2.2 mg/kg once-per-week expansion cohorts. The most common drug-related adverse events were fatigue, nausea, diarrhea, anorexia, vomiting, peripheral sensory neuropathy, and keratitis/keratopathy. There were no drug-related deaths. Anetumab ravtansine pharmacokinetics were dose proportional; the average half-life was 5.5 days. Among 148 patients with mesothelioma or ovarian, pancreatic, non–small-cell lung, and breast cancers, 1 had a complete response, 11 had partial responses, and 66 had stable disease. High levels of tumor mesothelin expression were detected in patients with clinical activity. CONCLUSION: Anetumab ravtansine exhibited a manageable safety and favorable pharmacokinetic profile with encouraging preliminary antitumor activity in heavily pretreated patients with mesothelin-expressing solid tumors. The results allowed for the determination of recommended doses, schedules, and patient populations for anetumab ravtansine in phase II studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 26
- 10.1073/pnas.93.1.136 · DOI · Paper page
- 10.1002/ijc.2910500308 · DOI · Paper page
- 10.1038/sj.bjc.6604964 · DOI · Paper page
- 10.1097/00000478-200302000-00002 · doi:10.1097/00000478-200302000-00002
- 10.1097/01.MP.0000056981.16578.C3 · DOI · Paper page
- 10.1158/0008-5472.CAN-14-0337 · DOI · Paper page
- 10.1200/JCO.2016.68.3672 · DOI · Paper page
- 10.1158/2159-8290.CD-15-0583 · DOI · Paper page
- 10.1186/1476-4598-5-50 · DOI · Paper page
- 10.1074/jbc.M312372200 · DOI · Paper page
- 10.1158/1078-0432.CCR-07-0869 · DOI · Paper page
- Hassan R, 2014, Cancer, 120, 3311, 10.1002/cncr.28875 · DOI · Paper page
- 10.1158/1078-0432.CCR-09-0062 · DOI · Paper page
- 10.1158/1535-7163.MCT-13-0926 · DOI · Paper page
- 10.3390/molecules22081281 · DOI · Paper page
- 10.1186/s13046-017-0667-1 · DOI · Paper page
- 10.1097/JTO.0b013e318208c83d · DOI
- 10.1016/j.ejca.2008.10.026 · DOI · Paper page
- 10.1200/JCO.2017.76.6394 · DOI · Paper page
- 10.1080/19420862.2016.1156829 · DOI · Paper page
- 10.1007/s10637-014-0151-0 · DOI
- 10.1200/JCO.2011.39.4403 · DOI · Paper page
- 10.1016/j.yrtph.2016.10.012 · DOI
- 10.1200/JCO.2011.39.6671 · DOI · Paper page
- 10.1016/j.jtho.2017.09.328 · DOI
- 10.1111/j.1600-0609.2007.00928.x · doi:10.1111/j.1600-0609.2007.00928.x
Cited by
Antibody–drug conjugates for cancer therapy
Thomas, A., Teicher, B. A., & Hassan, R. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30030-4 · Cited by 606
Self-citationAntibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
Clinical and translational advances in ovarian cancer therapy
Konstantinopoulos, P. A., & Matulonis, U. A. (2023) · Nature Cancer · doi:10.1038/s43018-023-00617-9 · Cited by 394
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Lambert, J. M., & Morris, C. Q. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0519-6 · Cited by 304
Metadata
- Authors
- Hassan, R., Blumenschein, G. R., Moore, K. N., Santin, A. D., Kindler, H. L., Nemunaitis, J. J., Seward, S. M., Thomas, A., Kim, S. K., Rajagopalan, P., Walter, A. O., Laurent, D., Childs, B. H., Sarapa, N., Elbi, C., & Bendell, J. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-06-01
- Volume
- 38
- Issue
- 16
- Pages
- 1824-1835
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3013332534
- Cited by
- 173
- References
- 0
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. https://app.cochat.ai/papers/10.1200/jco.19.02085
- The paper
- Hassan, R., Blumenschein, G. R., Moore, K. N., Santin, A. D., Kindler, H. L., Nemunaitis, J. J., Seward, S. M., Thomas, A., Kim, S. K., Rajagopalan, P., Walter, A. O., Laurent, D., Childs, B. H., Sarapa, N., Elbi, C., & Bendell, J. C. (2020). First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.02085
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.